Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Director Jason Aryeh sold 18,479 shares of Ligand Pharmaceuticals stock in a transaction dated Friday, November 25th. The shares were sold at an average price of $107.31, for a total transaction of $1,982,981.49. Following the completion of the sale, the director now owns 58,959 shares in the company, valued at approximately $6,326,890.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Jason Aryeh also recently made the following trade(s):

  • On Friday, November 18th, Jason Aryeh sold 6,330 shares of Ligand Pharmaceuticals stock. The shares were sold at an average price of $105.28, for a total transaction of $666,422.40.

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) opened at 104.91 on Tuesday. The firm’s 50-day moving average is $99.04 and its 200-day moving average is $112.20. The stock has a market capitalization of $2.19 billion, a P/E ratio of 300.60 and a beta of 1.43. Ligand Pharmaceuticals Inc. has a 52 week low of $82.06 and a 52 week high of $139.79.

Ligand Pharmaceuticals (NASDAQ:LGND) last announced its quarterly earnings results on Thursday, November 3rd. The biotechnology company reported $0.62 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.59 by $0.03. The business earned $21.62 million during the quarter, compared to the consensus estimate of $23.64 million. Ligand Pharmaceuticals had a net margin of 8.51% and a return on equity of 9.98%. The business’s revenue was up 22.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.57 EPS. On average, equities research analysts predict that Ligand Pharmaceuticals Inc. will post $3.40 EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

COPYRIGHT VIOLATION WARNING: This report was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was illegally copied and republished in violation of U.S. & international copyright laws. The correct version of this report can be accessed at http://www.dailypolitical.com/2016/11/29/jason-aryeh-sells-18479-shares-of-ligand-pharmaceuticals-inc-lgnd-stock.html.

Several analysts have recently issued reports on the stock. CJS Securities dropped their target price on shares of Ligand Pharmaceuticals from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Wednesday, September 28th. Roth Capital reiterated a “buy” rating and issued a $149.00 target price on shares of Ligand Pharmaceuticals in a research report on Wednesday, September 7th. Zacks Investment Research upgraded shares of Ligand Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $135.00 price target on the stock in a research report on Tuesday, August 9th. Vetr upgraded shares of Ligand Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $128.29 price target on the stock in a research report on Wednesday, August 10th. Finally, Deutsche Bank AG lowered shares of Ligand Pharmaceuticals from a “hold” rating to a “sell” rating and boosted their price target for the stock from $104.00 to $110.00 in a research report on Friday, August 5th. They noted that the move was a valuation call. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $139.70.

Institutional investors have recently made changes to their positions in the stock. D.A. Davidson & CO. increased its position in shares of Ligand Pharmaceuticals by 2.4% in the third quarter. D.A. Davidson & CO. now owns 1,722 shares of the biotechnology company’s stock worth $174,000 after buying an additional 40 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Ligand Pharmaceuticals by 3.6% in the third quarter. Price T Rowe Associates Inc. MD now owns 524,217 shares of the biotechnology company’s stock worth $53,502,000 after buying an additional 18,029 shares in the last quarter. Cornerstone Capital Management Holdings LLC. increased its position in shares of Ligand Pharmaceuticals by 56.7% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 3,871 shares of the biotechnology company’s stock worth $394,000 after buying an additional 1,400 shares in the last quarter. Ashford Capital Management Inc. increased its position in shares of Ligand Pharmaceuticals by 2.9% in the third quarter. Ashford Capital Management Inc. now owns 106,820 shares of the biotechnology company’s stock worth $10,902,000 after buying an additional 3,058 shares in the last quarter. Finally, Eaton Vance Management bought a new position in shares of Ligand Pharmaceuticals during the third quarter worth about $2,193,000.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.

5 Day Chart for NASDAQ:LGND

Receive News & Ratings for Ligand Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.